Kenvue Inc ousted its chief executive and announced a strategic review on Monday. Jefferies says KVUE shares could rally to $27.

Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, Sudafed, and Neutrogena into a new company called Kenvue, investor anticipation was high.

Nestled among the overflowing buffet of Tylenol products at your local pharmacy is Tylenol 8 Hour—the extended-release version of the original. The premise? Take a double dose half as often. The promise?

A new study into how Tylenol affects the central nervous system, blocking pain signals at origin, before they can reach the brain.

In 2008, the largest automotive recall in history occurred when Takata Corp. air bags in several brands of cars were found to be defective. Impacted brands included those made by BMW, Chrysler, Daimler Trucks, Ford, General Motors, Honda, Mazda, Mitsubishi, Nissan, Subaru and Toyota. At least 10 deaths were attributed to the defective air bags.

President Trump threatened new tariffs on Russia, Mexico and the EU. Plus: Crypto-sensitive stocks rose, as bitcoin prices rallied to another high. Kenvue shares rose after the maker of Tylenol and Benadryl named a new interim CEO.

According to a new study in rats, a key byproduct of acetaminophen, called AM404, may block pain at the source before it has a chance to reach the brain.

Painkiller: The Tylenol Murders — not to be confused with the 2023 Netflix series Painkiller, which was a fictionalized take on the opioid crisis — explores the case over the course of five 30 ...